Roche has recently received CE approval for its Accu-Chek SugarView blood glucose monitoring app. The approval will allow Roche to market glucose monitoring products aggressively and will further strengthen its leadership position in India’s glucose monitoring market, says GlobalData, a leading data and analytics company.

The company’s report, ‘Diabetes Care Devices – Insulin Pens – Global – 2015-2028’, reveals that the prevalence of type 2 diabetes in India is expected to grow from 8.8% in 2019 to 9.4% in 2028.

Rohit Anand, Medical Devices Analyst at GlobalData, comments: “The rising prevalent cases of diabetes is creating an unmet need for diagnosis, care and management of diabetic population in India. Monitoring diabetes digitally through an app will impact a large population and this could be a path-breaking solution for the diagnosis and management of diabetes in the long run.”

A very large mobile using population in India provides an equally large market opportunity to mobile health app developing companies. Currently, the available diabetes apps in India are used primarily to monitor blood glucose level trends and an individual needs to input these data points manually.

Accu-Chek SugarView can determine blood glucose ranges with the help of photos using a smartphone camera and test strips,  without the need of a blood glucose meter. It will help non-insulin-dependent type 2 diabetics or pre-diabetics to live a healthier life.  

Anand concludes: “Roche’s Accu-Chek SugarView app could disrupt the glucose monitoring devices market in India and is likely to have an impact on the traditional glucose meters as this app can be a possible replacement for older devices. Ease of use will surely encourage people to use this app but the accuracy of test results can fuel the adoption.”